test dose while the patients were in the ward under supervision. Propranolol is reputed not to have an immediate lowering effect on blood pressure and we were surprised to find a reduction over the four-hour period with the higher dose. This suggests that the use of low starting doses of propranolol leads to a slower onset of hypotensive action.
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Doubling the dose of propranolol in the outpatient study above 120 mg/day did not cause a statistically significant increase in the hypotensive effect. We have observed this lack of an increase in effect in a group of patients given the cardioselective beta-blocker atenolol, and the lack of an increase in effect has also been shown by others with oxprenolol.4 Within-patient comparisons of the doses used in this study with higher dosesfor example, 360 mg-4 g/day-would clearly be of interest.
Introduction
Phosphate-binding agents (such as aluminium hydroxide)
are widely used to reduce serum inorganic phosphate in patients with renal failure.1 2 These agents are known to cause phosphate depletion in patients with normal renal function3 and in patients with renal failure.45 Hypophosphataemic osteomalacia has been reported. 6 We have recently seen four patients who became hypophosphataemic and developed severe osteomalacia while receiving maintenance haemodialysis. Our experiences are reported in this paper.
Case 1
x-ray films showed a bone age of 11 years but were otherwise normal. Bone biopsy showed osteomalacia with an osteoid index8 of 5 0. Treatment with regular haemodialysis was started in July 1972, and oral aluminium hydroxide (2-4 g daily) was started four months later. The patient received phenytoin in doses ranging from 200-300 mg/day from July 1972 to May 1974. Serum calcium levels returned to normal within three months of the start of dialysis, while predialysis serum inorganic phosphate levels between October 1973 and May 1974 ranged from 0-55 to 1-2 mmol/l (1-7-3-6 mg/100 ml) (mean 0-71 mmol/l (2-2 mg/100 ml) ). Serum alkaline phosphatase gradually rose to 1150 IU/1. Serum immunoreactive parathyroid hormone levels ranged from 0-6-2-4~ig/l. On 9 May 1974 he was admitted with severe pain in the limbs and inability to walk. Pelvic x-ray examination showed Looser zones, and a repeat bone biopsy showed severe osteomalacia with an osteoid index of 30. The patient was treated with 2-5 mg dihydrotachysterol per day, and aluminium hydroxide treatment was discontinued. These measures were followed by complete symptomatic relief in six weeks. Predialysis serum inorganic phosphate levels rose to 1-3 mmol/l (4-0 mg/100 ml) or greater. Serum alkaline phosphatase activities initially rose to 2500 IU/l and fell to 200 IU/l three months later. The patient resumed aluminium hydroxide treatment and continued to take dihydrotachysterol (0 625 mg/day). [0] [1] [2] [3] [4] [5] [6] [7] [8] [9] mmol/l (2-8 mg/100 ml), and the mean predialysis calcium level was 2-45 mmol/l (9-8 mg/100 ml). Serum alkaline phosphatase gradually rose to 923 IU/l. The mean predialysis serum immunoreactive parathyroid hormone level was 4-2 ,ig/l.
In May 1974 he was admitted because of generalised muscle weakness and pain in the limbs which were so severe that he was unable to walk. Skeletal x-ray films showed rachitic changes, and a repeat bone biopsy showed an osteoid index of about 30. Aluminium hydroxide was withdrawn and dihydrotachysterol (0-625 mg/day) was prescribed.
Within four weeks the patient lost all symptoms. Predialysis serum phosphate levels rose to 1-9 mmol/l (6 mg/100 ml), and serum alkaline phosphatase levels rose to 1315 IU/1 after eight weeks and fell to 65 IU/1 within 12 months. In December 1974 he incurred a traumatic fracture of his right tibia and fibula which healed spontaneously. Since then he has received 0 6 g of aluminium hydroxide and 0-25 mg of dihydrotachysterol daily. The dialysate calcium concentration ranged from 1-8 to 2 0 mmol/l (7 3-8-0 mg/100 ml), the total phosphate from 0 03 to 0 06 mmol/l (0 1-0-2 mg/100 ml), and the fluoride from 0-95 to 1 0 parts per million. Dialysis regimens ranged from six to 12 hours three times a week.
Discussion
These patients illustrate a therapeutic dilemma relating to maintenance haemodialysis. On the one hand, prolonged hyperphosphataemia leads to hyperparathyroidism, soft tissue calcification, or both.' 2 16 On the other hand, phosphate-binding agents, which reduce serum inorganic phosphate, cause osteomalacia in experimental animals'7-9 and in man.3 6 Moreover, osteomalacia is present in a third of patients entering a haemodialysis programme,20 and in most cases this lesion becomes worse during the subsequent year.2' The question therefore arises whether it is possible to identify those patients who are vulnerable to the development of crippling osteomalacia.
All our patients were young, all had histological osteomalacia before starting haemodialysis, three showed radiological evidence of a reduced bone age, three were treated by domiciliary haemodialysis (24-30 hours/week), and three of them took aluminium hydroxide in doses and frequencies considered desirable by their medical attendants. Only one was taking barbiturates or phenytoin, drugs believed to aggravate osteomalacia in patients on maintenance haemodialysis.2' It is not clear which, if any, of these features are related to the pathogenesis of severe osteomalacia. Patients on domiciliary haemodialysis probably suffer greater phosphate losses5 than hospital patients, whose dialysis periods tend to be shorter.
Biochemical checks also tend to be less frequent in the domiciliary group. Phosphate-binding agents, which are known to lower serum inorganic phosphate (and are administered for this purpose), must clearly be regarded as one factor in the development of osteomalacia in this group of patients. Possibly the high prevalence of osteomalacia among patients at some dialysis centres reflects the compliance of the patients and the physician's attitude to "optimal" biochemical control.
Clinicians caring for patients receiving maintenance haemodialysis should prevent the development of hypophosphataemic osteomalacia by monitoring serum inorganic phosphate and alkaline phosphatase levels at monthly intervals. The serum phosphate concentration should range from 1-3 to 1-6 mmol/l (4-5 mg/100 ml) before dialysis with a fall to 0-8-1-2 mmol/l (2-5-3-7 mg/100 ml) after dialysis. Predialysis phosphate levels of 0 97 mmol/l (3 mg/100 ml) or less and a rising serum alkaline phosphatase should be considered as danger signals. Serum parathyroid hormone concentrations tend to be low in this syndrome. '6 i-When symptoms of malacia become manifest in a hypophosphataemic patient histological confirmation of the diagnosis should be obtained and early aggressive treatment of the condition undertaken to prevent the rapid development of disabling bone disease. Aluminium hydroxide should be temporarily withdrawn and vitamin D should be given. Withdrawal of aluminium hydroxide may, by itself, be sufficient23 but as these patients are likely to be suffering from abnormalities of vitamin D metabolism also24 some form of vitamin D seems indicated. In addition, Jones17 showed that hypophosphataemic rickets in rats could be prevented or cured by vitamin D.
Summary
The immediate short-term effect on plasma renin activity of intravenous injection of propranolol was studied in 31 normal subjects and 166 hypertensive patients. In patients with essential hypertension and normal subjects plasma renin activity fell considerably within 15 minutes; the fall was directly proportional to initial plasma renin levels. In contrast, in patients with renal hypertension the fall was much less pronounced or totally absent. These differences in response to propranolol provide, though presently only on a group basis, a biochemical means of differentiating between patients with renal hypertension and those with essential hypertension. The observations also indicate that, unlike normal subjects and patients with essential hypertension, in patients with renal hypertension sympathetic activity plays no part in the control of basal plasma renin levels.
Department of Medicine, University of Innsbruck, Innsbruck Introduction Precision in endocrine diagnosis depends on the ability to measure all components of the feedback loops controlling hormone secretion.' Nevertheless, renin levels in hypertensive patients are commonly still being interpreted without consideration of renal perfusion pressure, sodium concentration at the macula densa, or sympathetic tone at the juxtaglomerular apparatus, these probably being the main factors controlling renal renin release.2 None of the components of the feedback loops by which renin secretion is controlled is easily measurable in clinical practice. In an attempt to quantify sympathetic tone at the juxtaglomerular apparatus we have taken the immediate effect of acute beta-receptor blockade on basal plasma renin activity (PRA) as an indication of the extent to which renin release under basal conditions is mediated by the sympathetic nervous system. A preliminary account of part of this work has been published.3
Patients and methods
We studied (a) 31 
